SI2179737T1 - Modulacija reakcije na stereoide - Google Patents
Modulacija reakcije na stereoideInfo
- Publication number
- SI2179737T1 SI2179737T1 SI200631691T SI200631691T SI2179737T1 SI 2179737 T1 SI2179737 T1 SI 2179737T1 SI 200631691 T SI200631691 T SI 200631691T SI 200631691 T SI200631691 T SI 200631691T SI 2179737 T1 SI2179737 T1 SI 2179737T1
- Authority
- SI
- Slovenia
- Prior art keywords
- steroids
- oligonucleotide
- responding
- modulating responsiveness
- steroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69605005P | 2005-07-01 | 2005-07-01 | |
EP09167538.9A EP2179737B1 (en) | 2005-07-01 | 2006-06-30 | Modulating responsiveness to steroids |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2179737T1 true SI2179737T1 (sl) | 2014-02-28 |
Family
ID=37604740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631691T SI2179737T1 (sl) | 2005-07-01 | 2006-06-30 | Modulacija reakcije na stereoide |
Country Status (11)
Country | Link |
---|---|
US (2) | US8148341B2 (sl) |
EP (2) | EP2179737B1 (sl) |
JP (2) | JP5208734B2 (sl) |
AT (1) | ATE439135T1 (sl) |
DE (1) | DE602006008473D1 (sl) |
DK (1) | DK2179737T3 (sl) |
ES (2) | ES2330884T3 (sl) |
PL (1) | PL2179737T3 (sl) |
PT (1) | PT2179737E (sl) |
SI (1) | SI2179737T1 (sl) |
WO (1) | WO2007004979A1 (sl) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2380584B1 (en) * | 2005-07-01 | 2013-10-16 | Index Pharmaceuticals AB | Immunostimulatory method |
PL2179737T3 (pl) * | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
AU2006306805A1 (en) * | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
EP2656850B1 (en) * | 2007-10-05 | 2016-07-27 | InDex Pharmaceuticals AB | Oligonucleotides for the treatment or alleviation of edema |
WO2009054725A2 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
JP2011524899A (ja) * | 2008-06-18 | 2011-09-08 | インデックス・ファーマシューティカルズ・アクチエボラーグ | がんの併用療法 |
DK2350283T3 (en) * | 2008-11-04 | 2016-02-01 | Index Pharmaceuticals Ab | RELATIONS AND PROCEDURES FOR THE TREATMENT OF INFLAMMATORY DISEASES IN THE CENTRAL NERVOUS SYSTEM |
WO2012084991A1 (en) * | 2010-12-21 | 2012-06-28 | Index Pharmaceuticals Ab | Biologically active oligonucleotides capable of modulating the immune system ii |
EP2596806A1 (en) | 2011-11-25 | 2013-05-29 | Index Pharmaceuticals AB | Method for prevention of colectomy |
WO2013112053A1 (en) | 2012-01-27 | 2013-08-01 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
GB201707503D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New Therapy 3 |
GB201707501D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New therapy 2 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
TW244371B (sl) * | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
CA2105595A1 (en) | 1992-09-23 | 1994-03-24 | Ramaswamy Narayanan | Antisense polynucleotides |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
WO1997028259A1 (en) | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
SE9602300D0 (sv) | 1996-06-11 | 1996-06-11 | Karolinska Innovations Ab | New composition and methods |
JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 |
CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
ES2333069T3 (es) | 1997-03-10 | 2010-02-16 | Ottawa Hospital Research Institute | Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante. |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
CA2328602A1 (en) | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
EP1078053B1 (en) | 1998-05-14 | 2005-09-28 | Coley Pharmaceutical GmbH | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
DK1077722T3 (da) * | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
JP4663047B2 (ja) * | 1998-07-13 | 2011-03-30 | 株式会社半導体エネルギー研究所 | レーザー照射装置及び半導体装置の作製方法 |
JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | CpGオリゴヌクレオチドの立体異性体および関連する方法 |
EP1700603A3 (en) | 1999-09-25 | 2007-06-13 | Coley Pharmaceutical GmbH | Immunostimulatory nucleic acids |
IL148844A0 (en) | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
EP1688147A1 (en) | 1999-09-27 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US6649341B1 (en) * | 2000-04-19 | 2003-11-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Human glucocorticoid receptor 1A promoter and splice variants |
DE60139689D1 (de) | 2000-06-22 | 2009-10-08 | Univ Iowa Res Found | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
US20020198165A1 (en) * | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
US6943240B2 (en) * | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
US6294382B1 (en) * | 2000-11-27 | 2001-09-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of SRC-1 expression |
US20030055014A1 (en) * | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
JP2002257827A (ja) * | 2001-03-01 | 2002-09-11 | Jenokkusu Soyaku Kenkyusho:Kk | ステロイド応答性の検査方法 |
US20030050268A1 (en) | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
WO2002085308A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
JP4397571B2 (ja) * | 2001-09-25 | 2010-01-13 | 株式会社半導体エネルギー研究所 | レーザ照射方法およびレーザ照射装置、並びに半導体装置の作製方法 |
EP1451581A4 (en) * | 2001-10-05 | 2006-01-11 | Coley Pharm Gmbh | AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3 |
JP2005508945A (ja) * | 2001-10-06 | 2005-04-07 | メリアル リミテッド | Cpg配合物及び関連方法 |
US7105048B2 (en) * | 2001-11-30 | 2006-09-12 | Semiconductor Energy Laboratory Co., Ltd. | Laser irradiation apparatus |
JP3934536B2 (ja) * | 2001-11-30 | 2007-06-20 | 株式会社半導体エネルギー研究所 | レーザ照射装置およびレーザ照射方法、並びに半導体装置の作製方法 |
AU2003203079B9 (en) * | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
NZ573064A (en) * | 2002-04-04 | 2011-02-25 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
US6977775B2 (en) * | 2002-05-17 | 2005-12-20 | Sharp Kabushiki Kaisha | Method and apparatus for crystallizing semiconductor with laser beams |
JP4474108B2 (ja) * | 2002-09-02 | 2010-06-02 | 株式会社 日立ディスプレイズ | 表示装置とその製造方法および製造装置 |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US7625872B2 (en) | 2002-12-23 | 2009-12-01 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
SI1575977T1 (sl) | 2002-12-23 | 2010-01-29 | Dynavax Tech Corp | Imunostimulirni sekvenčni polinukleotidi in postopki za njihovo uporabo |
US7851453B2 (en) | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
WO2004085635A1 (en) * | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Melan-a peptide analogue-virus-like-particle conjugates |
CA2521050A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
EP1628531A4 (en) | 2003-05-16 | 2010-06-30 | Idera Pharmaceuticals Inc | SYNERGISTIC TREATMENT OF CANCER BY COMMON USE OF IMMUNOMER AND CHEMOTHERAPEUTICS |
US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
WO2005065678A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
US20050222072A1 (en) | 2004-02-20 | 2005-10-06 | Hybridon, Inc. | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
EP1716234B1 (de) | 2004-02-20 | 2013-10-02 | Mologen AG | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
SE0400399D0 (sv) | 2004-02-20 | 2004-02-20 | Index Pharmaceuticals Ab | Methods and compositions for the treatment or prevention of secondary ischemic injury |
RU2007101039A (ru) | 2004-06-15 | 2008-07-20 | Айдера Фармасьютикалз | Иммуностимулирующие олигонуклеотидные мультимеры |
JP5072197B2 (ja) * | 2004-06-18 | 2012-11-14 | 株式会社半導体エネルギー研究所 | レーザ照射装置およびレーザ照射方法 |
WO2006015560A1 (de) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
US8759305B2 (en) | 2004-09-01 | 2014-06-24 | Dynavax Technologies Corporation | Methods and compositions for inhibition of innate immune responses and autoimmunity |
RS20070422A (en) | 2005-04-08 | 2009-01-22 | Sanofi-Aventis U.S. Llc., | Methods for treating infectious disease exacerbated asthma |
EP2380584B1 (en) * | 2005-07-01 | 2013-10-16 | Index Pharmaceuticals AB | Immunostimulatory method |
PL2179737T3 (pl) * | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
-
2006
- 2006-06-30 PL PL09167538T patent/PL2179737T3/pl unknown
- 2006-06-30 EP EP09167538.9A patent/EP2179737B1/en active Active
- 2006-06-30 ES ES06748071T patent/ES2330884T3/es active Active
- 2006-06-30 PT PT91675389T patent/PT2179737E/pt unknown
- 2006-06-30 ES ES09167538T patent/ES2435531T3/es active Active
- 2006-06-30 AT AT06748071T patent/ATE439135T1/de not_active IP Right Cessation
- 2006-06-30 WO PCT/SE2006/050232 patent/WO2007004979A1/en active Application Filing
- 2006-06-30 DE DE602006008473T patent/DE602006008473D1/de active Active
- 2006-06-30 JP JP2008519236A patent/JP5208734B2/ja not_active Expired - Fee Related
- 2006-06-30 SI SI200631691T patent/SI2179737T1/sl unknown
- 2006-06-30 DK DK09167538.9T patent/DK2179737T3/da active
- 2006-06-30 US US11/917,748 patent/US8148341B2/en active Active
- 2006-06-30 EP EP06748071A patent/EP1904077B1/en not_active Not-in-force
-
2012
- 2012-03-01 US US13/410,121 patent/US8569257B2/en active Active
- 2012-07-03 JP JP2012149039A patent/JP5886699B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20120172420A1 (en) | 2012-07-05 |
JP2012193192A (ja) | 2012-10-11 |
JP5886699B2 (ja) | 2016-03-16 |
ES2435531T3 (es) | 2013-12-20 |
PL2179737T3 (pl) | 2014-01-31 |
EP1904077A1 (en) | 2008-04-02 |
JP5208734B2 (ja) | 2013-06-12 |
JP2008544984A (ja) | 2008-12-11 |
PT2179737E (pt) | 2013-12-05 |
DE602006008473D1 (de) | 2009-09-24 |
US20080318885A1 (en) | 2008-12-25 |
EP1904077B1 (en) | 2009-08-12 |
US8148341B2 (en) | 2012-04-03 |
WO2007004979A1 (en) | 2007-01-11 |
US8569257B2 (en) | 2013-10-29 |
ES2330884T3 (es) | 2009-12-16 |
EP2179737B1 (en) | 2013-08-14 |
ATE439135T1 (de) | 2009-08-15 |
EP2179737A2 (en) | 2010-04-28 |
EP2179737A3 (en) | 2010-08-25 |
DK2179737T3 (da) | 2013-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2179737T3 (pl) | Sposób do modulowania wrażliwości na steroidy | |
PT2269622E (pt) | Oligonucleotídeos cpg utilizados para aumentar a actividade dos esteróides num doente dependente de esteróides | |
MX2009000385A (es) | Acil-anilidas sustituidas y metodos de uso de las mismas. | |
HK1166983A1 (zh) | 包含用於治療疾病或紊亂的化合物的固體形式,其組合物,及其用途 | |
MX2010007936A (es) | Anticuerpo anti-nr-10 y su uso. | |
CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
BRPI0512944A (pt) | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 | |
DE60331236D1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
AR054233A1 (es) | Composiciones de anticuerpos igg2 | |
MX2009001962A (es) | Acilanilidas substituidas y metodos de uso de las mismas. | |
HK1125855A1 (en) | Use of oligouronates for treating mucus hyperviscosity | |
CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
EA200800869A1 (ru) | Модуляция экспрессии рецептора глюкагона | |
HK1110221A1 (en) | Use of prodrugs for ocular intravitreous administration | |
NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
BR112012004284B8 (pt) | ácidos biliares poli-hidroxilados para tratamento de transtornos biliares | |
IL189104A (en) | Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders. | |
WO2007135505A8 (en) | Veterinary pharmaceutical compositions for the treatment of pain and inflammation | |
IL198202A0 (en) | Peptide-cytotoxic conjugates | |
WO2007084359A3 (en) | Compositions and methods for the treatment of influenza infection | |
PL1612210T3 (pl) | Nowe analogi nitrobenzylotioinozyny | |
HUP0600489A2 (en) | Use of echinacea or preparations made thereof for the manufacture of pharmaceutical compositions for the treatment of anxiety | |
IL186286A0 (en) | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions | |
Clifton et al. | CAT OF THE MONTH. Critically Appraised Topics. The Cardiovascular Health Benefits of Oral Appliance Therapy for Obstructive Sleep Apnea Typically Outweigh the Risk of Tooth Movement and Malocclusion (UT CAT# 2808) |